ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologic agents"

  • Abstract Number: 1496 • 2019 ACR/ARP Annual Meeting

    Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study

    Josef Smolen1, Panagiotis Athanassiou 2, Paul Bergmans 3, Irina Bondareva 4, Kurt De Vlam 5, Elisa Gremese 6, Beatriz Joven-Ibáñez 7, Tatiana Korotaeva 8, Wim Noël 9, Michael Nurmohamed 10, Petros Sfikakis 11, Stefan Siebert 12, Pavel Smirnov 13, Elke Theander 14 and Laure Gossec 15, 1Medical University of Vienna, Vienna, Austria, 2General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, 3Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, 4GUZ Kemerovo Regional Clinical Hospital, Kemerovo, Russia, 5University Hospitals Leuven, Leuven, Belgium, 6Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, 7Hospital Universitario 12 de Octubre, Madrid, Spain, 8Nasonova Research Institute of Rheumatology, Moscow, Russia, 9Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, 10Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, 11Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 12Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 13Biostatistics and Medical Affairs, Janssen, Moscow, Russia, 14Biostatistics and Medical Affairs, Janssen, Solna, Sweden, 15Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France

    Background/Purpose: Among the treatment options for PsA, IL-12/23 inhibition with ustekinumab (UST) was the first new biologic mode of action after TNF inhibitors (TNFi). Few…
  • Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting

    Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?

    Santiago Rodrigues-Manica1, Alexandre Sepriano 2, Fernando Pimentel-Santos 1, Nélia Gouveia 3, Anabela Barcelos 4, Jaime Branco 1, Miguel Bernardes 5, Raquel Miriam-Ferreira 5, Elsa Vieira-Sousa 6, Sofia Barreira 6, Filipe Vinagre 7, Raquel Roque 7, Helena Santos 8, Nathalie Madeira 8, João Rovisco 9, Alexandra Daniel 9 and Sofia Ramiro 10, 1CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, 2Leiden University Medical Center, Leiden, Netherlands, 3CEDOC, NOVA-Medical School, Lisbon, Portugal, Lisboa, Portugal, 4Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, 5Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, 6Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, 7Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, 8Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 9Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Coimbra, Portugal, 10Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands

    Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…
  • Abstract Number: 1519 • 2019 ACR/ARP Annual Meeting

    Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)

    Gareth Jones1, Linda Dean 1, Ejaz Pathan 2 and Gary Macfarlane 1, 1University of Aberdeen, Aberdeen, United Kingdom, 2Toronto Western Hospital, Toronto, Canada

    Background/Purpose: In axial spondyloarthritis (axSpA), the clinical benefits of TNF inhibition (TNFi) are well documented although, by design, most studies report average benefits in groups…
  • Abstract Number: 1751 • 2019 ACR/ARP Annual Meeting

    A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis

    edoardo marrani1, Sarah Abu Rumeileh 1, Francesca Tirelli 2, Ilaria Maccora 3 and Gabriele Simonini 4, 1Post graduate School of pediatrics, University of Florence, Firenze, Italy, 2Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Firenze, Italy, 3Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Florence, Toscana, Italy, 4Anna Meyer Children's Hospital, Flotence, Italy

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune illness characterized by symmetric, proximal muscle damages and involvement of the skin. While first line treatment…
  • Abstract Number: 1802 • 2019 ACR/ARP Annual Meeting

    Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics

    Urmi Khanna1, Ariana Ellis 2, AbdulAziz Galadari 3, Jeffery Hu 4, Josh Gallop 5, M. Elaine Husni 6 and Anthony Fernandez 7, 1Department of Dermatology , Cleveland Clinic, Cleveland, OH, 2Northeast Ohio Medical University, Cleveland, OH, 3Cleveland Clinic, Abu Dhabi, Cleveland, 4Case Western Reserve University, Cleveland, 5Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 6Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 7Department of Dermatology and Pathology, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Guidelines for repeat Latent Tuberculosis Infection (LTBI) testing while on biologics are not clearly defined. The American College of Rheumatology recommends repeat LTBI screening…
  • Abstract Number: 1822 • 2019 ACR/ARP Annual Meeting

    6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Johan Askling 2, Catalin Codreanu 3, Herman Mann 4, Anne Gitte Loft 5, Manuel Pombo-Suarez 6, Ziga Rotar 7, Tore Kvien 8, Maria José Santos 9, Anna Mari Hokkanen 10, Florenzo Iannone 11, Bjorn Gudbjornsson 12, Fatos Onen 13, Lennart Jacobsson 14, Ruxandra IONESCU 15, Karel Pavelka 4, Carlos Sánchez-Piedra 16, Matija Tomsic 17, Joe Sexton 18, Helena Santos 19, Jenny Österlund 20, Alberto Cauli 21, Arni Jon Geirsson 22, Servet Akar 23, Adrian Ciurea 24, Gareth Jones 25, Irene van der Horst-Bruinsma 26, Cecilie Heegaard Brahe 27, Stylianos Georgiadis 28, Lykke Midtbøll Ørnbjerg 27, Mikkel Østergaard 29 and Merete Lund Hetland 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Karolinska Institutet, Stockholm, Sweden, 3Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 6Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 7UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 8Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10Helsinki University Hospital, Helsinki, Finland, 11Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 12Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 13Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, 14Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, 15SPITALUL CLINIC SFANTA MARIA, Bucharest, 16Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 17Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 18Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 19Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 20ROB-FIN registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland, 21Universitá di Cagliari, Cagliari, Italy, 22Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, 23Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 24University Hospital Zürich, Zürich, Switzerland, 25University of Aberdeen, Aberdeen, United Kingdom, 26Amsterdam University Medical Center, Amsterdam, Netherlands, 27Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 28DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 29Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 30DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Secukinumab is a fully human IgG1 monoclonal antibody targeting interleukin-17A. There is a lack of real-life evidence on secukinumab retention rates and treatment outcomes…
  • Abstract Number: 611 • 2018 ACR/ARHP Annual Meeting

    Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort

    Yoko Shimizu1, Eiichi Tanaka1, Eisuke Inoue1,2, Kumiko Saka1, Eri Sugano1, Naohiro Sugitani1,3, Moeko Ochiai1, Rei Yamaguchi1, Naoki Sugimoto1, Ayako Nakajima1,3, Katsunori Ikari1, Atsuo Taniguchi1 and Hisashi Yamanaka4, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, 3Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, 4Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: After the introduction of Biological Disease-Modifying Anti-Rheumatic-Drugs (bDMARDs) for the treatment of patients with active rheumatoid arthritis (RA), clinical remission has become an achievable…
  • Abstract Number: 2311 • 2018 ACR/ARHP Annual Meeting

    Effect of TNF Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate

    Jung Sun Lee1, Seokchan Hong2, Doo-Ho Lim3, Jebum Won1, Oh Chan Kwon2, Ji Seon Oh2, Yong-Gil Kim2, Chang Keun Lee2 and Bin Yoo2, 1Division of Rheumatology, Department of Internal Medicine,, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), 3Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)

    Background/Purpose: . This study aimed to investigate whether tumor necrosis factor inhibitors (TNFi) have beneficial effects on bone mineral density (BMD) in rheumatoid arthritis (RA)…
  • Abstract Number: 2876 • 2018 ACR/ARHP Annual Meeting

    Torque Teno Virus Quantification for Functional Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis

    Paul Studenic1, Gregor Bond2, Andreas Kerschbaumer3, Manuel Bécède3, Karel Pavelka4, Dmitry Karateev5, Jutta Stieger6, Rudolf Puchner7, Ruediger Mueller8, Elisabeth Puchhammer-Stöckl9, Martina Durechova10, Michaela Loiskandl10, Thomas Perkmann11, Marta Olejarova4, Elena Luchikhina12, Carl-Walter Steiner13, Michael Bonelli10, Josef S. Smolen14 and Daniel Aletaha10, 1Division of Rheumatology, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Internal Medicine 3, Division of Nephrology, Medical University of Vienna, Vienna, Austria, 3Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 4Department of Experimental Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University in Prague, Prague, Czech Republic, 5Department of Rheumatology, Department of Rheumatology, Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russian Federation, 62nd Deparment of Medicine, 2nd Deparment of Medicine, Hitzing Hospital, Vienna, Austria, 7Private Office, Wels, Austria, 8Division of Rheumatology, Immunology and Rehabilitation, Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St Gallen, St. Gallen, Switzerland, 9Institute for Virology, Institute for Virology, Medical University of Vienna, Vienna, Austria, 10Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 11Department of Laboratory Medicine, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, 12Department of rheumatology, Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russian Federation, 13Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 14Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Rheumatoid arthritis (RA) patients who fail to respond to methotrexate (MTX) can be subjected to an addition of biologic disease-modifying antirheumatic drug (bDMARD). Currently…
  • Abstract Number: 619 • 2018 ACR/ARHP Annual Meeting

    Patterns of Change of a Second Biological Dmard in a Cohort of Patients with Rheumatoid Arthritis

    Roger Rolon Campuzano1, Andrea Lujan Coronel Ale2, Osvaldo Cerda3,4,5, Fernando Dal Pra6, Emilce E Schneeberger7, María de los Angeles Correa3, Marcos G. Rosemffet8, Emilio Buschiazzo9, Rodrigo García Salinas10, Silvia Beatriz Papasidero11, Belén Barrios12, Hernán Maldonado Ficco13 and Gustavo Citera2, 1Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, 2Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina, 3Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 4Staff, Buenos Aires, Argentina, 5Sociedad Argentina de Reumatologia, CABA, Argentina, 6Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 7Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 8Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 9Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, 10Rheumatology Section, Hospital Italiano de La Plata, La Plata, Argentina, 11Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, Buenos Aires, Argentina, 12Rheumatology section, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, 13Rheumatology Section, Hospital San Antonio de Padua, Río Cuarto- Córdoba, Argentina

    Background/Purpose: Evaluate the survival of the 2nd biological disease modifying drug (bDMARD)and to determine the causes of suspension of the 2nd bDMARD. Methods: Patients ≥…
  • Abstract Number: 2394 • 2018 ACR/ARHP Annual Meeting

    Anti-Adalimumab Antibodies Kinetics: An Early Guide for Juvenile Idiopathic Arthritis (JIA) Switching

    Juliana Brunelli1, Clovis A Silva1, Sandra G Pasoto2, Carla GS Saad2, Katia T. Kozu1, Elaine P Leon2, Margarete B Vendramini2, Nicole Fontoura2, Eloisa Bonfa3 and Nadia E Aikawa2, 1Pediatric Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, 2Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, 3Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Anti-adalimumab antibody (AAA) production may lead to reduced adalimumab (ADA) serum levels and therapy failure. There are, however, scarce and conflicting data regarding ADA…
  • Abstract Number: 2907 • 2018 ACR/ARHP Annual Meeting

    Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings

    Asami Abe1, Hajime Ishikawa2 and Kunihiko Wakaki3, 1Rheumatology, Niigata Rheumatic Center, Shibata, Japan, 2Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, 3Pathology, Niigata Prefectural Shibata Hospital, Shibata, Japan

    Comparison of the joints ultrasonography in the patients with rheumatoid arthritis treated by biological agents and the corresponding synovial histological findings Background/Purpose: In the treatment…
  • Abstract Number: 688 • 2018 ACR/ARHP Annual Meeting

    Real Life Analysis of a Latin America Tertiary Spondyloarthritis Single-Center: High Frequency of Peripheral Involvement and Use of Synthetic Dmard

    Andrea Shimabuco1, Julio CB Moraes1, Percival Sampaio-Barros2, Cláudia Goldenstein-Schainberg1, Celio R. Gonçalves1, Ana CM Ribeiro1 and Carla GS Saad1, 1Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil

    Background/Purpose: The use of synthetic DMARDS (sDMARDs) in spondyloarthritis (SpA) has been increasingly questioned and restricted to peripheral disease, on the other hand, the use…
  • Abstract Number: 2449 • 2018 ACR/ARHP Annual Meeting

    Prevalence and Risk Factors of Serious Infections in Rheumatoid Arthritis Patients Receiving the Biologic/Targeted Synthetic Dmards: A Propensity Score Analysis from the Hong Kong Biologics Registry

    Chi Chiu Mok, Ting Hung Wan and Lai Shan Fong, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong

    Background/Purpose: To study the prevalence and risk factors for serious infections (SIs) in rheumatoid arthritis (RA) patients receiving the biologic / target synthetic (b/ts) DMARDs.…
  • Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting

    Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events

    Caitrin Coffey1, Michael Richter1, Cynthia S. Crowson2, Matthew J. Koster3, Kenneth J. Warrington4 and Ashima Makol3, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology